Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 2 , Pages 97-100 , March 2007

Fuzzy thinking on biomarkers

References 

  1. Dignam J, Bryant J, Paik S. Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy. Methods Mol Biol. 2002;184:169–189
  2. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456–1466
  3. Pajak TF, Clark GM, Sargent DJ, et al. Statistical issues in tumor marker studies. Arch Pathol Lab Med. 2000;124:1011–1015
  4. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69:979–985
  5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95
  6. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J Urol. 2006;175:820–834
  7. Joniau S, Goeman L, Pennings J, et al. Prostatic intraepithelial neoplasia (PIN): Importance and clinical management. Eur Urol. 2005;48:379–385
  8. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  9. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239–2246
  10. Bostwick DG. Grading prostate cancer. Am J Clin Pathol. 1994;102:S38–S56
  11. Carlson GD, Calvanese CB, Kahane H, et al. Accuracy of biopsy Gleason scores from a large uropathology laboratory: Use of a diagnostic protocol to minimize observer variability. Urology. 1998;51:525–529
  12. Sengupta S, Slezak JM, Blute ML, et al. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer. 2006;106:2630–2635
  13. Gonzalgo ML, Bastian PJ, Mangold LA, et al. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology. 2006;67:115–119
  14. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev. 2001;CD000486
  15. Iversen P, Rasmussen F, Christensen IJ. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl. 1994;157:41–47
  16. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984–3990
  17. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99–16. J Natl Cancer Inst. 2006;98:516–521
  18. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 1989;8:431–440
  19. Collette L, Burzykowski T, Carroll KJ, et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? (Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals). J Clin Oncol. 2005;23:6139–6148
  20. Roehrborn CG, Pickens GJ, Carmody T. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology. 1996;47:59–66
  21. Glenski WJ, Klee GG, Bergstralh EJ, et al. Prostate-specific antigen: Establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations. Prostate. 1992;21:99–110
  22. Herrmann M, Scharhag J, Sand-Hill M, et al. Long-distance mountain biking does not disturb the measurement of total, free or complexed prostate-specific antigen in healthy men. Clin Chem Lab Med. 2004;42:347–349
  23. Brawer MK, Bankson DD, Haver VM, et al. Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method. Prostate. 1997;30:269–273
  24. Jung K, Lein M, Brux B, et al. Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions. Clin Chem Lab Med. 2000;38:1271–1275
  25. Simon R, Radmacher MD, Dobbin K. Design of studies using DNA microarrays. Genet Epidemiol. 2002;23:21–36
  26. Sargent DJ, Conley BA, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23:2020–2027
  27. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  28. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512

PII: S1078-1439(06)00238-9

doi: 10.1016/j.urolonc.2006.10.005

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 2 , Pages 97-100 , March 2007

Article Tools

* Image Usage & Resolution